"We are very encouraged by the continued progress we have made in early 2026 to advance AD04 toward late-stage development, particularly in light of several important regulatory and strategic developments that we believe meaningfully strengthen our path forward," said Cary Claiborne, Chief Executive Officer of Adial. "Most notably, recent Food and Drug Administration (FDA) policy discussions indicating that, in certain scientifically justified cases, approval may be supported by one adequate and well-controlled study together with confirmatory evidence, rather than the traditional requirement of two independent pivotal trials, represents an increased emphasis on the FDA's existing flexibility in the development landscape. Given that Phase 3 trials are the most capital-intensive stage of development, this evolving framework could substantially reduce costs, improve capital efficiency, and accelerate our potential timeline to NDA submission."
"At the same time, we are seeing growing bipartisan support and regulatory momentum toward more patient-centered clinical trial endpoints in Alcohol Use Disorder (AUD), including measures such as reductions in heavy drinking, cravings, and overall disease severity, where such measures reflect clinically meaningful improvement for patients, rather than strict abstinence alone. This shift is further reinforced by recent Congressional action, including the introduction of bipartisan legislation aimed at expanding access to emerging therapies for veterans suffering from AUD, which supports investigational treatments aligned with the government's updated definition of recovery, including non-abstinence-based approaches and harm reduction outcomes. These developments are highly aligned with the clinical profile and intended real-world benefit of AD04, and we believe they further validate our approach to developing a differentiated, precision medicine treatment for AUD."
"From a strategic standpoint, we were also pleased to establish a collaboration framework with Molteni Farmaceutici, which represents an important first step toward building a commercial pathway for AD04 in Europe, subject to the execution of a definitive agreement. Molteni's deep expertise in addiction therapeutics and established infrastructure across European markets make them a strong potential partner as we look to expand AD04's global reach. In parallel, we continue to strengthen our intellectual property position, including the publication of our international patent application, which, if granted, is expected to extend protection for AD04 through at least 2045, further reinforcing the long-term value of our platform."
"Taken together, these regulatory developments, policy tailwinds, strategic partnerships, and IP advancements position us to advance AD04 with increasing clarity, efficiency, and confidence if we are able to obtain sufficient funding or a strategic partner. We are actively pursuing financing through various potential ...
